Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma
- PMID: 17201802
- DOI: 10.1111/j.1365-2265.2006.02685.x
Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma
Abstract
Objective: Most studies on the diagnostic value of serum thyroglobulin (Tg) concentrations in differentiated thyroid carcinoma (DTC) use fixed cut-off levels in heterogeneous groups of patients with respect to initial therapy and do not provide prognostic data. The objective was to investigate the prognostic values of serum Tg for disease-free remission and death, measured at fixed time-points after initial therapy using receiver operator characteristic (ROC) curve analyses.
Design: Single-centre observational study with 366 consecutive patients with DTC, who had all been treated according to the same protocol for initial therapy and follow-up.
Methods: Tg concentrations were measured at five fixed time-points after initial surgery. Tg cut-off values with the highest accuracy were calculated with ROC analyses.
Results: During the 8.3 +/- 4.6 years of follow-up, 84% of the patients were cured. Pre-ablative Tg levels were an independent prognostic indicator for disease-free remission (Tg cut-off value 27.5 microg/l, positive predictive value 98%). The highest diagnostic accuracies of serum Tg for tumour presence were found during TSH-stimulated Tg measurements, 6 months after initial therapy (Tg cut-off value 10 microg/l; sensitivity 100%, specificity 93%). DTC-related mortality was 14%. TSH-stimulated Tg levels before ablation and 6 months after initial therapy were independent prognostic indicators for death.
Conclusion: Optimal institutional Tg cut-off levels for diagnosis and prognosis should be defined using ROC analyses for each condition and time-point. Tg measurements 6 months after initial therapy during TSH stimulation had an excellent diagnostic value. Tg levels are independent prognostic indicators for disease-free remission and death. Using this strategy, high-risk patient groups can be selected based on Tg levels, in addition to conventionally used prognostic indicators.
Comment in
-
Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma?Nat Clin Pract Endocrinol Metab. 2007 Jul;3(7):510-1. doi: 10.1038/ncpendmet0532. Epub 2007 May 22. Nat Clin Pract Endocrinol Metab. 2007. PMID: 17519916 No abstract available.
Similar articles
-
Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.Clin Endocrinol (Oxf). 2008 Oct;69(4):659-63. doi: 10.1111/j.1365-2265.2008.03244.x. Epub 2008 Mar 18. Clin Endocrinol (Oxf). 2008. PMID: 18363882
-
Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):485-9. doi: 10.1055/s-2006-951778. Exp Clin Endocrinol Diabetes. 2006. PMID: 17115345
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
-
Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.Clin Endocrinol (Oxf). 2004 Jul;61(1):61-74. doi: 10.1111/j.1365-2265.2004.02060.x. Clin Endocrinol (Oxf). 2004. PMID: 15212646
-
Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls.Endocrinol Metab Clin North Am. 1995 Dec;24(4):841-63. Endocrinol Metab Clin North Am. 1995. PMID: 8608781 Review.
Cited by
-
Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.Arch Endocrinol Metab. 2024 Apr 4;68:e220506. doi: 10.20945/2359-4292-2022-0506. Arch Endocrinol Metab. 2024. PMID: 38578436 Free PMC article.
-
Analysis of the clinical factors affecting excellent response of Iodine-131 treatment for pulmonary metastases from differentiated thyroid cancer.Heliyon. 2023 Oct 13;9(11):e20853. doi: 10.1016/j.heliyon.2023.e20853. eCollection 2023 Nov. Heliyon. 2023. PMID: 37928010 Free PMC article.
-
Establishing a Cutoff Serum Thyroglobulin Value for the Diagnosis and Management of Well-Differentiated Thyroid Cancer.World J Nucl Med. 2023 Sep 6;22(3):208-216. doi: 10.1055/s-0043-1771286. eCollection 2023 Sep. World J Nucl Med. 2023. PMID: 37854090 Free PMC article.
-
Analysis of factors influencing the clinical outcome after surgery and 131I therapy in patients with moderate-risk thyroid papillary carcinoma.Front Endocrinol (Lausanne). 2022 Oct 14;13:1015798. doi: 10.3389/fendo.2022.1015798. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313750 Free PMC article.
-
Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience.Eur Thyroid J. 2021 Jul;10(5):408-415. doi: 10.1159/000516358. Epub 2021 May 25. Eur Thyroid J. 2021. PMID: 34540711 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous